Talus Biosciences

#Artificial intelligence (AI) #Collaboration #PRISM BioLab #Talus Biosciences #Transcriptomics

Talus Bio and PRISM BioLab collaborate on TF and PPI targets

Talus Bioscience and PRISM BioLab have agreed to join forces with the aim of accelerating the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets.   The collaboration combines Talus Bio’s regulome profiling and AI-guided drug discovery platform with PRISM’s chemistry platform.  “This collaboration… Read More

#Business & Investment #News

#Funding #Investment #Oncology #Talus Biosciences #Transcriptomics

Talus raises $11.2M to target undruggable transcription factors

Talus Bioscience has raised $11.2 million in new venture funding from a Seed+ round. The funding round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures. The money will be invested to advance Talus Bio’s therapeutic programmes, which… Read More

#Business & Investment #News